Literature DB >> 25683698

Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression.

Naghmeh Nikkheslat1, Patricia A Zunszain2, Mark A Horowitz2, Izabela G Barbosa2, Jennie A Parker3, Aye-Mu Myint4, Markus J Schwarz4, Andre T Tylee5, Livia A Carvalho6, Carmine M Pariante7.   

Abstract

Coronary heart disease (CHD) and depression are very common and often co-existing disorders. In addition to psychological and social morbidity, depression exacerbates adverse cardiac outcomes in CHD patients. Inflammation has been proposed as one of the mechanisms involved in the association between these two debilitating diseases. Therefore, the present study aimed to evaluate inflammatory responses as well as to investigate the pathophysiological mechanisms underlying the putative inflammatory activation in CHD patients with and without depression, by assessing the function of two important biological factors regulating inflammation, the hypothalamus-pituitary-adrenal (HPA) axis and the glucocorticoid receptor (GR). Eighty-three CHD patients with (n=28) and without (n=55) comorbid depression were recruited from primary care services in South London. Depression status was assessed by means of Clinical Interview Schedule Revised for diagnosis of depression, and Beck Depression Inventory for the presence of depressive symptoms. Serum C-reactive protein (CRP), plasma vascular endothelial growth factor (VEGF), and plasma and salivary cortisol were measured using commercially available ELISA kits. Gene expression of GR and interleukin-6 (IL-6) were conducted via qPCR. GR sensitivity was evaluated in vitro in isolated peripheral blood mononuclear cells using the dexamethasone inhibition of lipopolysaccharide-stimulated IL-6 levels. Serum levels of kynurenine pathway metabolites were measured using high performance liquid chromatography. Our results show that CHD patients with depression had higher levels of CRP, IL-6 gene expression, and VEGF compared with CHD non-depressed, as well as lower plasma and saliva cortisol levels. The CHD depressed group also exhibited a reduction in GR expression and sensitivity. Finally, tryptophan levels were significantly lower in patients with depression, who also showed an increased kynurenine/tryptophan ratio. In conclusion, CHD patients with depression had elevated levels of inflammation in the context of HPA axis hypoactivity, GR resistance, and increased activation of the kynurenine pathway. Reduced cortisol bioavailability and attenuated glucocorticoid responsiveness due to decreased expression and sensitivity of GR may lead to insufficient glucocorticoid signaling and thus elevation of inflammation in these patients.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk factors; Corticosteroid receptor; Cytokine; Kynurenine; Major depressive disorders; Neuroendocrine; Stress

Mesh:

Substances:

Year:  2015        PMID: 25683698     DOI: 10.1016/j.bbi.2015.02.002

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  37 in total

Review 1.  Depression in people with coronary heart disease: prognostic significance and mechanisms.

Authors:  Chris Dickens
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

2.  Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways.

Authors:  Mengqi Yang; Ruili Dang; Pengfei Xu; Yujin Guo; Wenxiu Han; Dehua Liao; Pei Jiang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-25       Impact factor: 4.530

3.  The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.

Authors:  Edward C Suarez; John S Sundy
Journal:  Health Psychol       Date:  2017-06-26       Impact factor: 4.267

4.  Fish oil supplementation attenuates neuroinflammation and alleviates depressive-like behavior in rats submitted to repeated lipopolysaccharide.

Authors:  Ruili Dang; Xueyuan Zhou; Mimi Tang; Pengfei Xu; Xiaoxue Gong; Yuanyuan Liu; Hongxiao Jiao; Pei Jiang
Journal:  Eur J Nutr       Date:  2017-01-05       Impact factor: 5.614

Review 5.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

6.  Exploring the Ovarian Reserve Within Health Parameters: A Latent Class Analysis.

Authors:  Theresa M Hardy; Mauricio Garnier-Villarreal; Donna O McCarthy; Richard A Anderson; Rebecca M Reynolds
Journal:  West J Nurs Res       Date:  2018-08-09       Impact factor: 1.967

7.  Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus.

Authors:  Jennifer C Felger; Ebrahim Haroon; Bobbi J Woolwine; Charles L Raison; Andrew H Miller
Journal:  Physiol Behav       Date:  2015-12-17

8.  HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling.

Authors:  Mandakh Bekhbat; C Christina Mehta; Sean D Kelly; Aimee Vester; Ighovwerha Ofotokun; Jennifer Felger; Gina Wingood; Kathryn Anastos; Deborah R Gustafson; Seble Kassaye; Joel Milam; Bradley Aouizerat; Kathleen Weber; Elizabeth T Golub; Michelle Floris Moore; Ralph Diclemente; Margaret Fischl; Mirjam-Colette Kempf; Pauline Maki; Gretchen N Neigh
Journal:  Psychoneuroendocrinology       Date:  2018-06-18       Impact factor: 4.905

9.  The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach.

Authors:  Xing Lv; Huijun Wang; Ruoming Wu; Xiaoyan Shen; Guan Ye
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-25       Impact factor: 2.629

10.  Glucocorticoid mediated regulation of inflammation in human monocytes is associated with depressive mood and obesity.

Authors:  Tiefu Cheng; Stoyan Dimitrov; Christopher Pruitt; Suzi Hong
Journal:  Psychoneuroendocrinology       Date:  2016-01-12       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.